Discover
spesolimab (BI 655130) / Boehringer IngelheimBI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis (clinicaltrials.gov) - May 22, 2020 - P2/3; N=98; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting --> Completed
synthetic biotic therapeutic / SynlogicSynlogic announces termination of AbbVie collaboration agreement (PRNewswire) - May 21, 2020 - "Synlogic, Inc....today announced the termination of its collaboration with AbbVie...for the development of Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD)....Upon termination, Synlogic regains all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows Synlogic to fully leverage its expertise in strain engineering, quantitative biology, regulatory, and manufacturing of living medicines to expand its wholly owned GI-based program portfolio to include IBD. Synlogic further regains the rights to partner its IBD programs."
filgotinib (GLPG0634) / GileadGilead and Galapagos announce positive topline results of phase 2b/3 trial of filgotinib in moderately to severely active ulcerative colitis (GlobeNewswire) - May 20, 2020 - P2b/3, N=1,351; SELECTION1 (NCT02914522); Sponsor: Gilead Sciences; "Gilead Sciences...and Galapagos...today announced positive topline results from SELECTION...Phase 2b/3 trial evaluating the efficacy and safety of...filgotinib...adult patients with moderately to severely active ulcerative colitis (UC). Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo. Filgotinib 100 mg did not achieve statistically significant clinical remission at Week 10."
Tremfya (guselkumab) / J&JA Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - May 21, 2020 - P3; N=25; Not yet recruiting; Sponsor: Janssen Pharmaceutical K.K.
mirikizumab (LY3074828) / Eli LillyLUCENT 2: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - May 19, 2020 - P3; N=1044; Recruiting; Sponsor: Eli Lilly and Company; Trial primary completion date: Jun 2021 --> Mar 2021
PF-06826647 / PfizerA Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis (clinicaltrials.gov) - May 20, 2020 - P2b; N=202; Recruiting; Sponsor: Pfizer; Not yet recruiting --> Recruiting
AMT-101 / Applied Molecular TransportInflammatory disease biotech Applied Molecular Transport files for a $100 million IPO (Nasdaq) - May 18, 2020 - "Applied Molecular Transport's pipeline contains lead candidate AMT-101...that has completed a Phase 1b trial for ulcerative colitis (UC). The company plans to initiate Phase 2 trials of AMT-101 in UC and related inflammatory indications between 2020 and 2021."
